ESR1 and breast carcinoma: Of note, univariate Cox-regression analysis of ER+/HER2− breast cancer samples from the HMF data showed that MYC amplification is significantly associated with everolimus-based treatment duration (HR = 2.70, P = 0.01; Fig. 9 F).